{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:15:15Z","timestamp":1791929715720,"version":"4.3.4"},"reference-count":15,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T00:00:00Z","timestamp":1739059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Selumetinib, a MEK1\/2 inhibitor, is commonly used for treating neurofibromatosis type 1 (NF1) and is associated with cutaneous side effects such as paronychia and periungual granulomas. These complications can be painful and difficult to manage, often leading to the discontinuation of treatment. The objective of this study was to evaluate the effectiveness of photodynamic therapy (PDT) as a novel treatment for MEKi-induced paronychia in a patient with NF1. Methods: We present a case report of an 18-year-old patient with NF1 who developed painful periungual granulomas on the toenails after 12 months of Selumetinib therapy. PDT was administered using methyl aminolevulinate (METVIX\u00ae) as the photosensitizing agent, followed by treatment with a red LED light source (630 nm, 37 J\/cm2 for 8 min and 30 s). The patient was followed up for two months post-treatment and then at two years. Results: After a single PDT session, the patient exhibited complete clinical remission of the periungual granulomas and associated pain. No recurrence of the lesions was noted during the two-year follow-up. The patient tolerated the procedure well, reporting only mild discomfort during treatment. Conclusions: PDT appears to be an effective, minimally invasive treatment for Selumetinib-induced paronychia and periungual granulomas. This case demonstrates that PDT can provide a complete resolution of symptoms with a single treatment session, offering an alternative to more invasive procedures. Further studies with larger cohorts are needed to establish PDT as a standard treatment option for this condition.<\/jats:p>","DOI":"10.3390\/jcm14041104","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T03:39:47Z","timestamp":1739158787000},"page":"1104","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Successful Treatment of MEK Inhibitor-Induced Paronychia in Neurofibromatosis with Photodynamic Therapy: A Case Report and Review of the Therapeutic Options"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5718-7003","authenticated-orcid":false,"given":"Francesca","family":"Ambrogio","sequence":"first","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Perillo","sequence":"additional","affiliation":[{"name":"Pediatric Hematology-Oncology Division, Department of Pediatrics, University of Bari, 70126 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1319-4946","authenticated-orcid":false,"given":"Domenico","family":"Bonamonte","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5829-2229","authenticated-orcid":false,"given":"Aurora","family":"De Marco","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Tirone","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5074-4951","authenticated-orcid":false,"given":"Carmelo","family":"Laface","sequence":"additional","affiliation":[{"name":"Medical Oncology, Azienda Ospedaliera S.Croce e Carle, 12100 Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0325-4316","authenticated-orcid":false,"given":"Gerardo","family":"Cazzato","sequence":"additional","affiliation":[{"name":"Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Foti","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3763-6922","authenticated-orcid":false,"given":"Edoardo","family":"Mortato","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1016\/S1470-2045(14)71133-7","article-title":"Nail toxicities induced by systemic anticancer treatments","volume":"16","author":"Robert","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2011.10.009","article-title":"The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-analysis","volume":"67","author":"Garden","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s10637-010-9567-3","article-title":"Dermatologic side effects associated with the MEK 1\/2 inhibitor selumetinib (AZD6244, ARRY 142886)","volume":"29","author":"Balagula","year":"2011","journal-title":"Investig. New Drugs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000444302","article-title":"Periungual Pyogenic Granuloma: The Importance of the Medical History","volume":"1","author":"Alessandrini","year":"2016","journal-title":"Skin Appendage Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"AB92","DOI":"10.1016\/j.jaad.2019.06.357","article-title":"MEK inhibitor-induced chronic paronychia","volume":"81","author":"Zhou","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2006.09.005","article-title":"Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management","volume":"56","author":"Hu","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jdin.2023.05.003","article-title":"Efficacy of available treatments for periungual and subungual pyogenic granulomas: A systematic review","volume":"12","author":"Cascardo","year":"2023","journal-title":"JAAD Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1111\/ajd.14079","article-title":"MEK inhibitor-induced paronychia in a paediatric population: A tertiary centre experience","volume":"64","author":"Palmeiro","year":"2023","journal-title":"Australas. J. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00520-018-4056-x","article-title":"Photodynamic therapy for periungual pyogenic granuloma-like lesions during chemotherapy: Our preliminary results","volume":"26","author":"Fabbrocini","year":"2018","journal-title":"Support Care Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Armstrong, A.E., Belzberg, A.J., Crawford, J.R., Hirbe, A.C., and Wang, Z.J. (2023). Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10996-y"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.jaad.2020.07.044","article-title":"Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: A multicenter study","volume":"84","author":"Boull","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/pde.14276","article-title":"Treatment of MEK inhibitor-induced paronychia with doxycycline","volume":"37","author":"Sun","year":"2020","journal-title":"Pediatr. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jdv.16044","article-title":"European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 2: Emerging indications\u2014Field cancerization, photorejuvenation and inflammatory\/infective dermatoses","volume":"34","author":"Morton","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jphotobiol.2009.07.001","article-title":"Porphyrin synthesis from aminolevulinic acid esters in endothelial cells and its role in photodynamic therapy","volume":"96","author":"Rodriguez","year":"2009","journal-title":"J. Photochem. Photobiol. B"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/s41416-019-0586-3","article-title":"Systemic MEK inhibition enhances the efficacy of 5-aminolevulinic acid-photodynamic therapy","volume":"121","author":"Chelakkot","year":"2019","journal-title":"Br. J. Cancer"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/4\/1104\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:29:48Z","timestamp":1760027388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/4\/1104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,9]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jcm14041104"],"URL":"https:\/\/doi.org\/10.3390\/jcm14041104","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,9]]}}}